Recruiting
Phase 2

ILKN421H & Pembrolizumab

Sponsor:

iLeukon Therapeutics, Inc.

Code:

NCT07452224

Conditions

Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ILKN421H

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-22. This information was provided to ClinicalTrials.gov by iLeukon Therapeutics, Inc. on 2026-07-10.